Table 1.

Best corrected visual acuity (measured by Snellen decimal notation) at baseline and at benchmark follow-up visits in both the groups

	Baseline	1st month	3rd month	6th month	12th month
Aflibercept group	0.17±0.05 (0.1–0.25)	0.39±0.21 (0.1–0.7)	0.35±0.2 (0.05–0.7)	0.37±0.24 (0.2–0.8)	0.42±0.28 (0.1–0.8)
Ranibizumab group	0.18±0.04 (0.1–0.3)	0.34±0.19 (0.1–0.7)	0.33±0.19 (0.1–0.6)	0.41±0.19 (0.05–0.7)	0.37±0.23 (0.05–0.7)
P-value	0.9	0.83	0.7	0.87	0.27

Note: The data in this table are presented as mean ± SD (range).